ACADIA Pharmaceuticals (ACAD) Shares are Down -9.06%

ACADIA Pharmaceuticals (ACAD) has risen sharply, recording gains of 0.7% in the past 4 weeks. However, the stock has corrected -9.06% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.24% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.99% and the 50-Day Moving Average is 6.53%.The 200 Day SMA reached 5.48%


ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened in the green at $32.71 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $32.77 and a low of $31.25 for the day. The stock did not find buyers even at the lows and closed at $31.81 recording a loss of -2.72%. 2,397,545 shares exchanged hands during the trading day. The stock had closed at $31.81 in the previous days trading.

ACADIA Pharmaceuticals (ACAD) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $60 and the lowest price target forecast is $39. The average forecast of all the analysts is $46.29 and the expected standard deviation is $7.16.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *